« Return to News | CROs/Service Providers

Kendle Reports 50% Income Drop, Suspends Guidance for 2009

Thursday, August 6, 2009 08:04 AM

Kendle’s net income was cut almost 50% in the second quarter 2009 with income dropping to $3.2 million, or $0.21 per diluted share, compared with net income of $6.3 million, or $0.42 per diluted share in Q2 2008. Net revenues for the quarter were $107.4 million, down from $127 million during the same period last year.

The contract research organization also announced that it is suspending financial guidance for 2009 “due to a combination of factors” and will reassess its guidance policy in 2010. Kendle CEO Candace Kendle did not comment on the financial results when they were released Thursday night. Kendle’s shares rose nine cents to $11.96 in after hours trading.

Earlier this month, Kendle reorganized its executive suite and created the new role of chief administrative officer (CAO) to increase innovation, productivity and organizational efficiency, the company said. Kendle’s chief operating officer Christopher Bergen assumed the role of executive vice president and CAO, while former Quintiles executive Stephen Cutler, Ph.D., replaced Bergen as COO and senior vice president.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.